Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 8/2018

01-08-2018 | Original Article

Rush Fracture Liaison Service for capturing “missed opportunities” to treat osteoporosis in patients with fragility fractures

Authors: M.J. Gupta, S. Shah, S. Peterson, S. Baim

Published in: Osteoporosis International | Issue 8/2018

Login to get access

Abstract

Summary

In spite of being a public health problem of pandemic proportions, osteoporosis continues to be underdiagnosed and undertreated especially in older adults with fragility fractures. Confirmation of this hypothesis resulted in the development of a novel Fracture Liaison Service (Rush FLS). Results of the first 12 months of operation revealed that patients with confirmed fragility fracture do not have a timely diagnosis at fracture occurrence or treatment of their disease. The Rush FLS is an effective fracture liaison model.

Introduction

Determining the prevalence of undiagnosed and untreated osteoporosis in fragility fracture patients, either admitted to an academic tertiary care center or treated and discharged from the center’s emergency department to be followed in the endocrinology bone clinic, using an innovative, educational, low-cost, physician-run Fracture Liaison Service (FLS).

Methods

An automated alert was integrated into the electronic medical record at Rush University Medical Center (RUMC), triggered by historical and/or acute fracture(s) in patients 50 years or older, in patients that were either admitted to the hospital or in patients evaluated in the emergency department and discharged to be followed in the endocrinology bone clinic. We report the results of the first 12 months of operation in patients admitted to the hospital.

Results

First acute fragility fracture(s) were identified in 36% (80/223), only historical fragility fracture(s) in 28% (63/223) and both acute and historical fragility fracture(s) in 36% (80/223). The cumulative subgroup with historical fragility fractures with/without new fractures included 67% (96/143) without a previous diagnosis of osteoporosis. First acute fragility fracture group included 83.8% (67/80) without a previous diagnosis of osteoporosis. Rush FLS “captured missed opportunities” in 73.1% (163/223) of previously undiagnosed and 77.1% (172/223) of previously untreated osteoporosis patients. Dual-energy x-ray absorptiometry (DXA) prior to FLS consult was confirmed in 30% (67/223). Vitamin D deficiency (25-hydroxy vitamin D < 20 ng/ml) in 41.9% (78/186) including undetectable levels in 16.6% (31/186) and secondary hyperparathyroidism in 43.3% (78/180) were the most common laboratory confirmed secondary etiologies for bone loss.

Conclusions

This study reported undiagnosed, uninvestigated, and untreated osteoporosis in the majority of fragility fracture patients seen by the Rush FLS in the first 12 months of operation.
Literature
1.
Strom O, Borgstrom F, Kanis JA, Compston J, Cooper C, McCloskey EV, Jönsson B (2011) Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6:59–155. https://​doi.​org/​10.​1007/​s11657-011-0060-1 CrossRefPubMed
2.
Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22(3):465–475CrossRefPubMed
3.
Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 7:1726CrossRef
4.
Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407–413CrossRefPubMed
5.
International Osteoporosis Foundation. Capture the fracture. www.catpurethefracture.org/health-economics
6.
Leboime A, Confavreux CB, Mehsen N, Paccou J, David C, Roux C (2010) Osteoporosis and mortality. Joint Bone Spine 77(2):S107–S112CrossRefPubMed
7.
Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382CrossRefPubMed
8.
Gallagher JC, Melton LJ, Riggs BL, Bergstrath E (1980) Epidemiology of fractures of the proximal femur in Rochester, Minnesota. Clin Orthop Relat Res 150:163–171
9.
E Michael Lewiecki. Womens Health 2015;11(3):269–271
10.
Kanis JA, Borgstrom F, Zethraeus N, Johnell O, Oden A, Bengt J (2005) Intervention thresholds for osteoporosis in the UK. Bone 36(1):22–32CrossRefPubMed
11.
Dawson-Hughes B, Harris SS, Krall EA, Dallal GE (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337:670–676CrossRefPubMed
12.
Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7):637–645CrossRefPubMed
13.
McClung M.R., Lewiecki M, Cohen S.B, Bolognese M.A., Woodson G.C, Moffett A.H., Peacock M, Miller P.D, Lederman S.N, Chesnut C.H, Lain D., Kivitz A.J., Holloway D.L., Zhang, C., Peterson M.C.and Bekker P.J., for the AMG 162 Bone Loss Study Group (2006). Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821–831.
14.
McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Wasnich RD, Greenwald M, Kaufman JM, Chesnut CH, Reginster JY ((2001)) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333–340
15.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer P, Eriksen EF, Cummings S (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822CrossRefPubMed
16.
Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;7–348(9041):1535–41
17.
Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999 ;13;282(14):1344–52
18.
Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998). Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998 Dec 23-30;280(24):2077-82
19.
Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CAF, Hu M, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, Effect of abaloparatide vs placebo on New vertebral fractures in postmenopausal women with osteoporosis, a randomized clinical trial. JAMA 2016;16;316 (7):722–33
20.
Lyles KW, Colon-Emeric CS, Magaziner JS (2007) HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809CrossRefPubMed
21.
Freedman KB, Kaplan FS, Bilker WB, Strom BL, Lowe RA (2000) Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am 82-A:1063–1070CrossRefPubMed
22.
Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 29:1929–1937CrossRefPubMedPubMedCentral
23.
Harrington J (2006) Dilemmas in providing osteoporosis care for fragility fracture patients. US Musculoskelet Rev Touch Brief II 2006:64–65
24.
Åkesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, Kyer C, Cooper C (2013) Capture the fracture: a best practice frame work and global campaign to break the fragility fracture cycle. Osteoporos Int 24:2135–2152CrossRefPubMedPubMedCentral
25.
26.
27.
McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, Adekunle F, Roberts D (2011) Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int 22(7):2083–2098CrossRefPubMed
28.
Dell R, Greene D, Schelkun SR, Williams K (2008) Osteoporosis disease management: the role of the orthopaedic surgeon. J Bone Joint Surg Am 90(Suppl 4):188–194CrossRefPubMed
29.
Newman ED, Ayoub WT, Starkey RH, Diehl JM, Wood GC (2003) Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years. Osteoporos Int 14:46–151CrossRef
30.
Bunta A, Edwards B, Macaulay W, Jeray K, Tosi L, Jones C, Sietsema D, Kaufman J, Murphy S, Song, J, Goulet G, Friedlaender S, Wiontkowski M, Dirschl D. Own the bone, a system-based intervention, improves osteoporosis care after fragility fractures. J Bone Joint Surg Am. 2016;98:e109(1–8)
31.
Nakayama A, Major G, Holliday E, Attia J, Bogduk N ((2016)) Evidence of effectiveness of a fracture liaison service to reduce the refracture rate. Osteoporos Int 27:873–879
32.
The Joint Commission. Osteoporosis-Associated Fracture Implementation Guide. 2013.Revised 2016. https://​www.​jointcommission.​org/​assets/​1/​6/​Osteoporosis_​Imp_​Guide_​2013;16318.pdf
33.
Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporosis Int 25(10):2359–2381CrossRef
34.
http://www.who.int/classifications/icd/ICD10 Volume2_en_2010.pdf
35.
Brown JP, Josse RG (2002) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167:S1–34
36.
Jewelwicz R, Schwartz M (1986) Premature ovarian failure. Bull N Y Acad Med 62:219–236
37.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M (2010) Sarcopenia: European consensus on definition and diagnosis—report of the European working group on sarcopenia in older people. Age Ageing 39:412–423CrossRefPubMedPubMedCentral
38.
39.
40.
Suhm N, Lamy O, Lippuner K (2008) OsteoCare study group management of fragility fractures in Switzerland: results of a nationwide survey. Swiss Med Wkly 138:674–683PubMed
41.
Gong HS, Oh WS, Chung MS, Oh JH, Lee YH, Baek GH (2009) Patients with wrist fractures are less likely to be evaluated and managed for osteoporosis. J Bone Joint Surg Am 91:2376–2380CrossRefPubMed
42.
Harrington JT, Broy SB, Derosa AM, Licata AA, Shewmon DA (2002) Hip fracture patients are not treated for osteoporosis: a call to action. Arthritis Rheum 47:651–654CrossRefPubMed
43.
Khan SA, de Geus C, Holroyd B, Russell AS (2001) Osteoporosis follow-up after wrist fractures following minor trauma. Arch Intern Med 161:1309–1312CrossRefPubMed
44.
Jennings LA, Auerbach AD, Maselli J, Pekow PS, Lindenauer PK, Lee SJ (2010) Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc 58:650–657CrossRefPubMedPubMedCentral
Metadata
Title
Rush Fracture Liaison Service for capturing “missed opportunities” to treat osteoporosis in patients with fragility fractures
Authors
M.J. Gupta
S. Shah
S. Peterson
S. Baim
Publication date
01-08-2018
Publisher
Springer London
Published in
Osteoporosis International / Issue 8/2018
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-018-4559-9

Other articles of this Issue 8/2018

Osteoporosis International 8/2018 Go to the issue

Original Article

Fermented dairy products consumption is associated with attenuated cortical bone loss independently of total calcium, protein, and energy intakes in healthy postmenopausal women

Letter

At what price decreased mortality risk?

Original Article

Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway

Original Article

Characteristics of recurrent fractures

Review

Impact of muscle atrophy on bone metabolism and bone strength: implications for muscle-bone crosstalk with aging and disuse

Original Article

Subtrochanteric and diaphyseal femoral fractures in hypophosphatasia—not atypical at all